The global biosimilar & biologics market size is expected to expand from US$ 520.9 billion in 2024 to a staggering US$ 1,060.7 billion by 2034. It will likely exhibit robust growth, with overall sales of biosimilars & biologics rising at 7.6% CAGR.
Global Biosimilar and Biologics Market Insights
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | US$ 480.1 billion |
| Estimated Biosimilar and Biologics Market Value (2024) | US$ 520.9 billion |
| Estimated Biosimilar & Biologics Market Revenue (2034) | US$ 1,060.7 billion |
| Value CAGR (2024 to 2034) | 7.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Global biosimilar and biologic sales grew at a CAGR of 5.8% from 2019 to 2023. Total market valuation at the end of 2023 reached around US$ 480.1 billion at the end of 2023. Over the forecast period, the global market for biosimilars and biologics is set to expand at 7.6% CAGR.
The pharmaceutical industry has seen significant advancements in developing and manufacturing biosimilars and biologics, presenting numerous opportunities for innovation, growth, and improved patient access to essential therapies. Advances in biotechnology and manufacturing technologies have enabled more efficient and cost-effective production of biologics and biosimilars.
Manufacturers of the original biologics can leverage bio-better development strategies to reinforce their market position and defend against competition, including biosimilars, by offering upgraded versions of their products with enhanced sensitivity. Novel expression systems, cell culture techniques, and purification methods have improved biological products' yield, purity, and consistency, driving down production costs and increasing scalability.
Sophisticated analytical techniques, manufacturing processes, and the introduction of artificial intelligence have facilitated in-depth characterization and comparability assessment of biosimilars with their reference products. These analytical advancements ensure biosimilars' quality, safety, and efficacy, supporting regulatory approval and market acceptance.
Regulatory agencies globally have established clear pathways and guidelines for developing and approving biosimilars. These established pathways reduce barriers to entry for biosimilar developers, encouraging competition and market growth.
The biosimilar market is increasingly globalizing, with manufacturers from both developed and emerging countries participating in biosimilar and biologic development and commercialization. Nations like India, China, and South Korea are emerging as key players in the biosimilar & biologic landscape, offering cost-competitive manufacturing capabilities.
Multiple factors limit the expansion of the global biosimilar and biologics market globally. These include regulatory complexities, high development costs, and supply chain issues.
Biosimilars require extensive clinical trials and data to demonstrate their safety and similarity to original biologics. This leads to lengthy and expensive development processes, thereby limiting market expansion to some extent.
Biosimilars and biologics necessitate specific handling protocols, including refrigeration and stringent processing, to prevent contamination by microorganisms and other impurities. Given that these products are typically administered via injection or intravenous infusion, maintaining sterility is very important to avoid a lethal impact on the patient’s life.
Due to their distinctive characteristics and the complexities involved in their production and distribution, biologics are often categorized as specialty drugs. Adherence to stringent good manufacturing practices (GMP), guidelines, and regulations is essential to ensure that manufacturing facilities are designed, operated, and maintained to minimize contamination risks and uphold aseptic conditions.
Another factor that may affect the uptake of biosimilars is that a biosimilar generally cannot be automatically substituted for the reference product (i.e., brand-name biologic) at the pharmacy level unless it is determined to be interchangeable with the reference product. An interchangeable product should have the same effect as the original product for each patient.
Unlike generic drugs, where substitution at the pharmacy level is typically automatic, biosimilars cannot be automatically substituted for the reference product unless they have been determined to be interchangeable by regulatory authorities. This is negatively impacting market growth.
An interchangeable biosimilar should meet specific criteria set by regulatory agencies, such as the CDSCO in India and the FDA in the United States. These criteria typically include demonstrating that the biosimilar produces the same clinical result as the reference product in any given patient and that switching between the biosimilar and the reference product does not pose greater risk than using the reference product alone.
The table below shows the estimated growth rates of the top five countries. The United States, China, and Spain are set to record high CAGRs of 5.9%, 8.8%, and 7.4%, respectively, through 2034.
Market Growth Outlook by Key Countries
| Countries | Value CAGR |
|---|---|
| United States | 5.9% |
| China | 8.8% |
| Japan | 4.0% |
| Germany | 4.6% |
| Spain | 7.4% |
The United States is expected to dominate the global biosimilar & biologics market during the forecast period. It will likely register steady growth, with overall demand for biosimilars and biologics rising at a CAGR of 5.9% through 2034.
China is emerging as a highly lucrative market for biosimilars & biologics, and the trend will likely persist during the forecast period. As per the latest analysis, sales of biosimilars and biologics in China are anticipated to grow at 8.8% CAGR through 2034.
The table section offers deeper insights into leading segments in the global industry. The information will likely help companies maximize profits and stay ahead of the curve.
Market Growth Outlook by Drug Class
| Drug | Value CAGR |
|---|---|
| Monoclonal Antibody | 5.7% |
| Vaccines | 9.4% |
| Recombinant Insulin | 7.8% |
| Growth factors | 6.7% |
| Immune Modulators | 8.5% |
| Fusion Protein | 6.9% |
| Erythoprotein | 11.1% |
| Therapeutic Enzymes | 10.1% |
| Interferons | 12.9% |
| Colony Stimulation Factors | 11.9% |
| Oligonucleotides | 13.9% |
| Others Drug | 5.8% |
As per the latest analysis, the monoclonal antibody segment is expected to dominate the global biosimilar & biologic industry during the forecast period. It will likely rise at a CAGR of 5.7%, generating revenue worth US$ 161.1 billion in 2024.
Market Growth Outlook by Source
| Source | Value CAGR |
|---|---|
| Bacterial Cells | 6.7% |
| Yeast Cells | 8.2% |
| Plant Cells | 9.9% |
| Animal Cells | 7.4% |
| Other Sources | 8.8% |
Bacterial cells are widely used for producing biosimilars and biologics. This is due to their multiple advantages, including faster and cheaper production, scalability, and lower immunogenicity.
The bacterial cells segment is estimated to account for a dominant market share of 44.0% in 2024. Further, it will likely witness a CAGR of 6.7% during the forecast period, totaling a valuation of US$ 229.2 billion in 2024.
Market Growth Outlook by Application
| Application | Value CAGR |
|---|---|
| Oncology | 6.2% |
| Autoimmune Disease | 6.9% |
| Infectious Diseases | 8.9% |
| Rare Disease | 9.7% |
| Cardiovascular Disorders | 10.6% |
| Hematological Disorders | 7.8% |
| Others Application | 8.3% |
Based on application, the oncology segment is anticipated to generate significant revenue for the biosimilar & biologics market. It will likely grow at a CAGR of 6.2% during the assessment period, totaling US$ 134.8 billion in 2024. This can be attributed to factors like:
Increased life expectancy and improved diagnostics lead to more cancer diagnoses, driving the need for effective treatments. Advancements in personalized medicine require diverse treatment options customized to individual patients' mutations and tumor profiles. Biologics and biosimilars offer this diversity.
The prevalence of cancer is increasing globally due to factors such as aging population, lifestyle changes, and environmental factors. As cancer rates rise, there is a greater need for effective treatments, including biologics.
Biologics, including monoclonal antibodies and targeted therapies, have become standard treatments for lung cancer. These pharmaceuticals possess improved efficacy and reduced toxicity compared to traditional chemotherapy.
Market Growth Outlook by Manufacturing Type
| Manufacturing Type | Value CAGR |
|---|---|
| Contract Manufacturing | 7.4% |
| In-house Manufacturing | 7.9% |
The contract manufacturing industry is expected to lead the biosimilar and biologic industry during the assessment period, holding a share of 56.7% in 2024. Over the forecast period, the target segment will likely exhibit a CAGR of 7.4%.
Market Growth Outlook by Distribution Channel
| Distribution Channel | Value CAGR |
|---|---|
| Hospital Pharmacies | 6.8% |
| Retail Pharmacies | 7.7% |
| Specialty Pharmacies | 8.2% |
| Mail Order Pharmacies | 8.8% |
In terms of distribution channel, the hospital pharmacies segment is poised to exhibit a CAGR of 6.8% during the forecast period. It will likely account for a revenue share of 37.5% in 2024.
Key manufacturers of biosimilars and biologics are rigorously investing in research and development to develop novel solutions for different applications, including cancer treatments. They are employing strategies like collaborations, mergers, acquisitions, partnerships, facility expansions, and distribution agreements to expand their footprint and stay ahead of the competition.
Recent Developments in the Biosimilar and Biologics Market
The global biosimilar & biologics market value is set to reach US$ 520.9 billion in 2024.
By 2034, the biologics and biosimilar market size is expected to reach US$ 1,060.7 billion.
The global market for biosimilars & biologics increased at 5.8% CAGR from 2019 to 2023.
Demand for biosimilar & biologics is projected to grow at 7.6% CAGR.
With 31.0% share in 2023, the monoclonal antibody segment dominated the global market.
The United States biosimilar & biologics market is estimated to grow at 5.9% CAGR.
Biosimilar & biologic sales in China are estimated to surge at 8.8% CAGR through 2034.
Biologics are medications derived from living organisms, while biosimilars are medications similar to existing biologics.
The biologics market was valued at around US$ 335.4 billion in 2021.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Development/Innovation Trends 4. Value-Added Insights 4.1. Product Adoption Analysis 4.2. Disease Epidemiology 4.3. Pipeline Analysis 4.4. Regulatory Guidelines 4.4.1. Legal Requirements and Frameworks in the United States 4.4.2. Legal Requirements and Frameworks in Europe 4.4.3. Legal Requirements and Frameworks in Japan 4.4.4. Legal Requirements and Frameworks in China 4.4.5. Legal Requirements and Frameworks in India 4.5. Unmet Needs Analysis 4.6. PESTEL Analysis 4.7. Porters Analysis 4.8. Value Chain Analysis 4.9. Biosimilar Development 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure 5.1.2. R & D funding by Region 5.1.3. R & D funding by Country 5.2. Forecast Factors - Relevance and Impact 5.2.1. Regulatory Environment 5.2.2. Patent Expirations 5.2.3. Healthcare Expenditure 5.2.4. Biosimilar Pipeline 5.2.5. Clinical Evidence and Physician Acceptance 5.2.6. Market Access and Distribution Channels 5.2.7. Therapeutic Area Dynamics 5.2.8. Biosimilar Competition 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ billion) Analysis 2019 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market Value (US$ billion) Analysis, 2019 to 2023 6.2. Revenue Opportunity Analysis 6.3. Current and Future Market Value (US$ billion) Projections, 2024 to 2034 6.3.1. Y-o-Y Growth Trend Analysis 6.3.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ billion) Analysis By Drug Class, 2019 to 2023 7.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Drug Class, 2024 to 2034 7.3.1. Monoclonal Antibody 7.3.2. Vaccines 7.3.3. Recombinant Insulin 7.3.4. Growth Factors 7.3.5. Immune Modulators 7.3.6. Fusion Protein 7.3.7. Erythoprotein 7.3.8. Therapeutic Enzymes 7.3.9. Interferons 7.3.10. Colony Stimulation Factors 7.3.11. Oligonucleotides 7.3.12. Others Drug 7.4. Market Attractiveness Analysis By Drug Class 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Source 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ billion) Analysis By Source, 2019 to 2023 8.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Source, 2024 to 2034 8.3.1. Bacterial Cells 8.3.2. Yeast Cells 8.3.3. Plant Cells 8.3.4. Animal Cells 8.3.5. Other Sources 8.4. Market Attractiveness Analysis By Source 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ billion) Analysis By Application, 2019 to 2023 9.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Application, 2024 to 2034 9.3.1. Oncology 9.3.2. Autoimmune Disease 9.3.3. Infectious Diseases 9.3.4. Rare Disease 9.3.5. Cardiovascular Disorders 9.3.6. Hematological Disorders 9.3.7. Other Application 9.4. Market Attractiveness Analysis By Application 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Manufacturing Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ billion) By Manufacturing Type, 2019 to 2023 10.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Manufacturing Type, 2024 to 2034 10.3.1. Contract Manufacturing 10.3.2. In-house Manufacturing 10.4. Market Attractiveness Analysis by Manufacturing Type 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ billion) By Distribution Channel, 2019 to 2023 11.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Distribution Channel, 2024 to 2034 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Specialty Pharmacies 11.3.4. Mail Order Pharmacies 11.4. Market Attractiveness Analysis by Manufacturing Type 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ billion) Trend Analysis by Region, 2019 to 2023 12.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Region, 2024 to 2034 12.3.1. North America 12.3.2. Latin America 12.3.3. East Asia 12.3.4. South Asia and Pacific 12.3.5. Western Europe 12.3.6. Eastern Europe 12.3.7. Middle East and Africa 12.4. Market Attractiveness Analysis by Region 13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 13.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. United States 13.3.1.2. Canada 13.3.1.3. Mexico 13.3.2. By Drug Class 13.3.3. By Source 13.3.4. By Application 13.3.5. By Manufacturing Type 13.3.6. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Source 13.4.4. By Application 13.4.5. By Manufacturing Type 13.4.6. By Distribution Channel 13.5. Market Trends 13.6. Drivers and Restraints Impact Analysis 13.7. Country-Wise Analysis 13.7.1. United States Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Drug Class 13.7.1.2.2. By Source 13.7.1.2.3. By Application 13.7.1.2.4. By Manufacturing Type 13.7.1.2.5. By Distribution Channel 13.7.2. Canada Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Drug Class 13.7.2.2.2. By Source 13.7.2.2.3. By Application 13.7.2.2.4. By Manufacturing Type 13.7.2.2.5. By Distribution Channel 13.7.3. Mexico Market Analysis 13.7.3.1. Introduction 13.7.3.2. Market Analysis and Forecast by Market Taxonomy 13.7.3.2.1. By Drug Class 13.7.3.2.2. By Source 13.7.3.2.3. By Application 13.7.3.2.4. By Manufacturing Type 13.7.3.2.5. By Distribution Channel 14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 14.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Chile 14.3.1.3. Rest of Latin America 14.3.2. By Drug Class 14.3.3. By Source 14.3.4. By Application 14.3.5. By Manufacturing Type 14.3.6. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Source 14.4.4. By Application 14.4.5. By Manufacturing Type 14.4.6. By Distribution Channel 14.5. Market Trends 14.6. Drivers and Restraints Impact Analysis 14.7. Key Market Players Intensity Mapping 14.8. Country-Wise Analysis 14.8.1. Brazil Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug Class 14.8.1.2.2. By Source 14.8.1.2.3. By Application 14.8.1.2.4. By Manufacturing Type 14.8.1.2.5. By Distribution Channel 14.8.2. Chile Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Drug Class 14.8.2.2.2. By Source 14.8.2.2.3. By Application 14.8.2.2.4. By Manufacturing Type 14.8.2.2.5. By Distribution Channel 15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 15.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Class 15.3.3. By Source 15.3.4. By Application 15.3.5. By Manufacturing Type 15.3.6. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Source 15.4.4. By Application 15.4.5. By Manufacturing Type 15.4.6. By Distribution Channel 15.5. Market Trends 15.6. Drivers and Restraints Impact Analysis 15.7. Country-Wise Analysis 15.7.1. China Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Drug Class 15.7.1.2.2. By Source 15.7.1.2.3. By Application 15.7.1.2.4. By Manufacturing Type 15.7.1.2.5. By Distribution Channel 15.7.2. Japan Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Drug Class 15.7.2.2.2. By Source 15.7.2.2.3. By Application 15.7.2.2.4. By Manufacturing Type 15.7.2.2.5. By Distribution Channel 15.7.3. South Korea Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Drug Class 15.7.3.2.2. By Source 15.7.3.2.3. By Application 15.7.3.2.4. By Manufacturing Type 15.7.3.2.5. By Distribution Channel 16. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 16.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. India 16.3.1.2. ASEAN Countries 16.3.1.3. Australia and New Zealand 16.3.1.4. Rest of South Asia and Pacific 16.3.2. By Drug Class 16.3.3. By Source 16.3.4. By Application 16.3.5. By Manufacturing Type 16.3.6. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Source 16.4.4. By Application 16.4.5. By Manufacturing Type 16.4.6. By Distribution Channel 16.5. Market Trends 16.6. Drivers and Restraints Impact Analysis 16.7. Country-Wise Analysis 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Drug Class 16.7.1.2.2. By Source 16.7.1.2.3. By Application 16.7.1.2.4. By Manufacturing Type 16.7.1.2.5. By Distribution Channel 16.7.2. ASEAN Countries Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Drug Class 16.7.2.2.2. By Source 16.7.2.2.3. By Application 16.7.2.2.4. By Manufacturing Type 16.7.2.2.5. By Distribution Channel 16.7.3. Australia and New Zealand Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Drug Class 16.7.3.2.2. By Source 16.7.3.2.3. By Application 16.7.3.2.4. By Manufacturing Type 16.7.3.2.5. By Distribution Channel 17. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 17.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. Italy 17.3.1.3. France 17.3.1.4. United Kingdom 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Rest of Western Europe 17.3.2. By Drug Class 17.3.3. By Source 17.3.4. By Application 17.3.5. By Manufacturing Type 17.3.6. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Source 17.4.4. By Application 17.4.5. By Manufacturing Type 17.4.6. By Distribution Channel 17.5. Market Trends 17.6. Drivers and Restraints Impact Analysis 17.7. Country-Wise Analysis 17.7.1. Germany Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Drug Class 17.7.1.2.2. By Source 17.7.1.2.3. By Application 17.7.1.2.4. By Manufacturing Type 17.7.1.2.5. By Distribution Channel 17.7.2. Italy Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Drug Class 17.7.2.2.2. By Source 17.7.2.2.3. By Application 17.7.2.2.4. By Manufacturing Type 17.7.2.2.5. By Distribution Channel 17.7.3. France Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Drug Class 17.7.3.2.2. By Source 17.7.3.2.3. By Application 17.7.3.2.4. By Manufacturing Type 17.7.3.2.5. By Distribution Channel 17.7.4. United Kingdom Republic Market Analysis 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Drug Class 17.7.4.2.2. By Source 17.7.4.2.3. By Application 17.7.4.2.4. By Manufacturing Type 17.7.4.2.5. By Distribution Channel 17.7.5. Spain Market Analysis 17.7.5.1. Introduction 17.7.5.2. Market Analysis and Forecast by Market Taxonomy 17.7.5.2.1. By Drug Class 17.7.5.2.2. By Source 17.7.5.2.3. By Application 17.7.5.2.4. By Manufacturing Type 17.7.5.2.5. By Distribution Channel 17.7.6. BENELUX Market Analysis 17.7.6.1. Introduction 17.7.6.2. Market Analysis and Forecast by Market Taxonomy 17.7.6.2.1. By Drug Class 17.7.6.2.2. By Source 17.7.6.2.3. By Application 17.7.6.2.4. By Manufacturing Type 17.7.6.2.5. By Distribution Channel 18. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 18.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 18.3.1. By Country 18.3.1.1. Russia 18.3.1.2. Hungary 18.3.1.3. Poland 18.3.1.4. Rest of Eastern Europe 18.3.2. By Drug Class 18.3.3. By Source 18.3.4. By Application 18.3.5. By Manufacturing Type 18.3.6. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Source 18.4.4. By Application 18.4.5. By Manufacturing Type 18.4.6. By Distribution Channel 18.5. Market Trends 18.6. Drivers and Restraints Impact Analysis 18.7. Country-Wise Analysis 18.7.1. Poland Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Drug Class 18.7.1.2.2. By Source 18.7.1.2.3. By Application 18.7.1.2.4. By Manufacturing Type 18.7.1.2.5. By Distribution Channel 18.7.2. Hungary Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Drug Class 18.7.2.2.2. By Source 18.7.2.2.3. By Application 18.7.2.2.4. By Manufacturing Type 18.7.2.2.5. By Distribution Channel 18.7.3. Russia Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Drug Class 18.7.3.2.2. By Source 18.7.3.2.3. By Application 18.7.3.2.4. By Manufacturing Type 18.7.3.2.5. By Distribution Channel 19. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 19.1. Introduction 19.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023 19.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034 19.3.1. By Country 19.3.1.1. Saudi Arabia 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. Other African Union 19.3.1.5. Rest of Middle East & Africa 19.3.2. By Drug Class 19.3.3. By Source 19.3.4. By Application 19.3.5. By Manufacturing Type 19.3.6. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Class 19.4.3. By Source 19.4.4. By Application 19.4.5. By Manufacturing Type 19.4.6. By Distribution Channel 19.5. Market Trends 19.6. Drivers and Restraints Impact Analysis 19.7. Country-Wise Analysis 19.7.1. Saudi Arabia Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Drug Class 19.7.1.2.2. By Source 19.7.1.2.3. By Application 19.7.1.2.4. By Manufacturing Type 19.7.1.2.5. By Distribution Channel 19.7.2. Türkiye Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Drug Class 19.7.2.2.2. By Source 19.7.2.2.3. By Application 19.7.2.2.4. By Manufacturing Type 19.7.2.2.5. By Distribution Channel 19.7.3. South Africa Market Analysis 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Drug Class 19.7.3.2.2. By Source 19.7.3.2.3. By Application 19.7.3.2.4. By Manufacturing Type 19.7.3.2.5. By Distribution Channel 19.7.4. Other African Union Market Analysis 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Drug Class 19.7.4.2.2. By Source 19.7.4.2.3. By Application 19.7.4.2.4. By Manufacturing Type 19.7.4.2.5. By Distribution Channel 20. Market Structure Analysis 20.1. Company Share Analysis 20.2. Market Presence Analysis 21. Competition Analysis 21.1. Branding and Promotional Strategies 21.2. Competition Deep Dive 21.2.1. Pfizer Inc. 21.2.1.1. Overview 21.2.1.2. Service Portfolio 21.2.1.3. Key Financials 21.2.1.4. SWOT Analysis 21.2.1.5. Key Developments 21.2.1.6. Strategy Overview 21.2.1.6.1. Marketing Strategy 21.2.1.6.2. Product Strategy 21.2.1.6.3. Channel Strategy 21.2.2. F.Hoffmann-La Roche AG 21.2.3. AbbVie Inc. 21.2.4. Novartis AG 21.2.5. Merck and Co., Inc. 21.2.6. Bristol Myers Squibb Co. 21.2.7. GSK plc 21.2.8. AstraZeneca 21.2.9. Eli Lilly and Co. 21.2.10. Bayer AG. 21.2.11. Gilead Sciences 21.2.12. Amgen Inc. 21.2.13. Boehringer Ingelheim International GmbH 21.2.14. Novo Nordisk A/S 21.2.15. Viatris Inc. 21.2.16. Johnson and Johnson (Janssen Pharmaceuticals, Inc.) 21.2.17. Sanofi Winthrop Industries S.A (1/4) 21.2.18. Serum Institute of India 21.2.19. Biocon Limited 21.2.20. Intas Pharmaceuticals Limited 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Biosimilar and Biologics Market
